Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa Inhibitors

Nature Communications - United Kingdom
doi 10.1038/s41467-017-00647-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Factor Xa Inhibitors

2016English

Rivaroxaban: An Oral Direct Inhibitor of Factor Xa

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2008English

Phosphatidylserine and Factor VA Regulate Factor Xa Structure

Biophysical Journal
Biophysics
2014English

Antithrombin-Independent Thrombin Inhibitors, but Not Direct Factor Xa Inhibitors, Enhance Thrombin Generation in Plasma Through Inhibition of Thrombin-Thrombomodulin-Protein C System

Thrombosis and Haemostasis
Hematology
2011English

Safety of 4-Factor Prothrombin Complex Concentrate (4f-Pcc) for Emergent Reversal of Factor Xa Inhibitors

Journal of Intensive Care
Critical CareIntensive Care Medicine
2018English

Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?

Clinical Orthopaedics and Related Research
MedicineSurgeryOrthopedicsSports MedicineSports Science
2017English

Antithrombotic Drug and Its Clinical Indication. Factor Xa Inhibitor. Oral Xa Inhibitor (DX-9065a).

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1996English

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

American Journal of Medicine
Medicine
2016English

Ixolaris: A Factor Xa Heparin-Binding Exosite Inhibitor

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy